Decitabine
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Lymphocytic Leukemia
Conditions
Acute Lymphocytic Leukemia
Trial Timeline
Jul 1, 2006 → Oct 1, 2014
NCT ID
NCT00349596About Decitabine
Decitabine is a phase 1 stage product being developed by Eisai for Acute Lymphocytic Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00349596. Target conditions include Acute Lymphocytic Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Lymphocytic Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00538876 | Phase 1 | Completed |
| NCT00477386 | Phase 1/2 | Completed |
| NCT00398983 | Phase 2/3 | Completed |
| NCT00349596 | Phase 1 | Completed |
| NCT00760084 | Phase 2 | Completed |
| NCT00260065 | Phase 2 | Completed |
| NCT00358644 | Phase 2 | Completed |
| NCT00113321 | Phase 2 | Terminated |
Competing Products
20 competing products in Acute Lymphocytic Leukemia